Spatially encoded biological assays

• US 10,472,669 B2
• Filed: 05/02/2019
• Issued: 11/12/2019
• Est. Priority Date: 04/05/2010
• Status: Active Grant

• Current Assignee: Prognosys Biosciences Inc.
• Original Assignee: Prognosys Biosciences Inc.
• Inventors: Chee, Mark S.
• Primary Examiner(s): Martinell, James
• Application Number:
  US16/402,098
• Publication Number:
  US 20190271030A1
• Time in Patent Office: 194 Days
• Field of Search: None
• CPC Class Codes: B01L 3/502715 characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
• CPC Class Codes: C12Q 1/6804 Nucleic acid analysis using immunogens immunoassay G01N33/53
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6841 In situ hybridisation
• CPC Class Codes: C12Q 1/6869 Methods for sequencing
• CPC Class Codes: C12Q 1/6874 involving nucleic acid arrays, e.g. sequencing by hybridisation
• CPC Class Codes: C12Q 2535/122 Massive parallel sequencing
• CPC Class Codes: C12Q 2543/10 the purpose being "in situ" analysis
• CPC Class Codes: C12Q 2563/179 the label being a nucleic acid
• CPC Class Codes: C12Q 2565/515 characterised by the interaction between or sequential use of two or more arrays
• CPC Class Codes: C40B 30/04 by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• CPC Class Codes: C40B 60/04 Integrated apparatus specially adapted for both screening libraries and identifying library members
• CPC Class Codes: G01N 2458/10 Oligonucleotides as tagging agents for labelling antibodies
• CPC Class Codes: G01N 33/5308 for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
• CPC Class Codes: G01N 33/543 with an insoluble carrier for immobilising immunochemicals
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures

Abstract

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Claims

1. A method of associating presence or abundance of a target biological molecule with a location of interest of a tissue sample, comprising:

delivering a plurality of probes to a tissue sample, wherein at least one probe of the plurality of probes comprises a protein that specifically binds a target biological molecule of the tissue sample, wherein the protein is conjugated to an oligonucleotide having a sequence, and

wherein (i) each of the at least one probe comprises a protein that specifically binds a different target biological molecule of the tissue sample, and (ii) the protein of each of the at least one probe is conjugated to a different oligonucleotide having a sequence;

imaging the tissue sample to identify a location of interest of the tissue sample; and

sequencing all or a portion of the sequence(s) of the oligonucleotide(s) or a complement thereof, from the at least one probe specifically bound to the target biological molecule(s) in the location of interest of the tissue sample, and using the determined sequence(s) to associate presence or abundance of the target biological molecule(s) with the location of interest of the tissue sample.

2. The method of claim 1, wherein the at least one probe is two or more probes.

3. The method of claim 2, wherein the sequence of the oligonucleotides of the two or more probes is determined in parallel.

4. The method of claim 2, wherein the sequence of the oligonucleotides of the two or more probes are determined sequentially.

5. The method of claim 2, wherein the determined sequence(s) are used to associate the presence or abundance or both, of each of the two or more target biological molecules with the location of interest of the tissue sample in parallel.

6. The method of claim 2, wherein the determined sequence(s) are used to associate the presence or abundance or both, of each of the two or more target biological molecules with the location of interest of the tissue sample sequentially.

7. The method of claim 1, wherein the target biological molecule(s) comprises a protein.

8. The method of claim 7, wherein the two or more probes is at least one thousand probes.

9. The method of claim 8, wherein the two or more probes is at least five thousand probes.

10. The method of claim 1, wherein the sequencing step is performed by nucleic acid sequencing or high-throughput sequencing.

11. The method of claim 1, wherein the plurality of probes is delivered to multiple sites in the tissue sample.

12. The method of claim 11, wherein the method further comprises detecting differential expression of the target biological molecule(s) in one or more of the multiple sites of the tissue sample.

13. The method of claim 12, wherein the differential expression of the target biological molecule(s) is associated with a biological structure or cell type in the one or more of the multiple sites of the tissue sample.

14. The method of claim 11, wherein one or more of the multiple sites are determined by histological features of the tissue sample.

15. The method of claim 1, further comprising, before the sequencing step, separating the at least one probe specifically bound to the target biological molecule(s) in the location of interest of the tissue sample from the plurality of probes not specifically bound to the target biological molecule(s) in the location of interest of the tissue sample.

16. The method of claim 15, wherein the separating step comprises washing.

17. The method of claim 1, wherein the tissue sample comprises a fresh-frozen or formalin fixed paraffin embedded (FFPE) tissue sample.

18. The method of claim 1, further comprising identifying a location of the target biological molecule(s) in one or more serial sections of the tissue sample.

19. The method of claim 18, further comprising generating a 3-dimensional map of the target biological molecule(s) in the tissue sample.

20. The method of claim 1, further comprising determining activity of the target biological molecule(s) at the location of interest of the tissue sample.

21. The method of claim 1, wherein the determined sequence(s) are used to associate the presence of the target biological molecule(s) with the location of interest of the biological sample.

22. The method of claim 1, wherein the determined sequence(s) are used to associate the abundance of the target biological molecule(s) with the location of interest of the biological sample.

23. The method of claim 1, wherein the determined sequence(s) are used to associate the presence and abundance of the target biological molecule(s) with the location of interest of the biological sample.

24. The method of claim 1, wherein one or more of the at least one probe comprises an antibody that specifically binds a target biological molecule of the tissue sample.

25. The method of claim 1, further comprising conducting a nucleic acid amplification reaction using the oligonucleotide(s) prior to the sequencing step.

26. The method of claim 25, wherein the nucleic acid amplification reaction is an extension reaction.

27. The method of claim 1, wherein the tissue sample is a tissue sample affixed to a support.

28. The method of claim 1, wherein the tissue sample is at least one tissue section.

29. The method of claim 28, wherein the location of the target biological molecule is within the at least one tissue section.

30. The method of claim 1, wherein imaging comprises detecting at least one probe specifically bound to a target biological molecule of the tissue sample.